Alpha-synuclein Education and Disclosure in Individuals With Preclinical and Symptomatic Lewy Body Disease

Korábbi kezelés

• Concurrent enrollment in a trial with conflicting disclosure protocols.
  • Healthy/Asymptomatic Arm • Neurological diagnosis at the time of biomarker assessment (e.g., Alzheimer's disease, Parkinson's disease, normal pressure hydrocephalus, brain tumor, progressive supranuclear palsy, seizure disorder, subdural hematoma, etc.)
  • Symptomatic Arm

Egyéb

• All Participants
• Clinician judgment that disclosure poses unacceptable psychological risk.
• Absence of a caregiver who can complete assessments.

• All Participants
• Able to provide 1) written, informed consent or 2) assent if a care partner can provide consent.
• Access to a primary care or neurology provider for ongoing care.
• 1) willing to undergo skin biopsy or lumbar puncture for alpha-synuclein testing or 2) has access to as-yet undisclosed skin biopsy or lumbar puncture alpha-synuclein testing results.
  • Healthy/Asymptomatic Arm
• Undergoing testing for defined reason (e.g., research study)
• Mini-Mental State Examination score between 26 and 30 (or MoCA between 25 and 30)
• General good health (no diseases expected to interfere with the study)
  • Symptomatic Arm [Concern for dementia with Lewy bodies (DLB), Parkinson's disease (PD), or multiple system atrophy (MSA)]
• Referred by a neurologist or movement disorder specialist
• Adults with any of the following: symptomatic LBD, mild cognitive impairment with Lewy body (MCI-LB), Parkinson's disease dementia (PDD), MCI in Parkinson's disease (PD-MCI), or criteria for multiple system atrophy (MSA).